The global project to share COVID-19 vaccines is struggling to place more than 300 million doses in the latest sign the problem with vaccinating the world is now more about demand than supply.
At least $18 billion is needed to get the fight against malaria, tuberculosis and AIDS back on track from disruptions caused by the COVID-19 pandemic, a global health fund said on February 23.
The U.S. Centers for Disease Control and Prevention is under fire for failing to publish large swaths of hospitalization data related to the COVID-19 pandemic that the organization has collected but failed to make public.
Hong Kong is in “all-out combat” to contain a surge in coronavirus cases, the city’s number two official said on February 20, with the ramping up of community isolation and treatment units helped by mainland Chinese construction teams.
President Joe Biden said on February 18 the U.S. national emergency declared in March 2020 due to the COVID-19 pandemic will be extended beyond March 1 due to the ongoing risk to public health posed by the coronavirus.
Early in the COVID-19 pandemic, there was a lot of talk about the “new normal,” with most people wanting to get back to the “old normal.” Two-plus years into the pandemic, it’s obvious that COVID-19 is not going away, prompting discussion about what this “new normal” will actually look like.
Misinformation about science is increasingly prevalent and a significant public health threat that the U.S. Food and Drug Administration will focus on fighting, incoming Commissioner Robert Califf said on February 17.
Top U.S. infectious disease expert Dr. Anthony Fauci said on February 16 that it is time for the United States to start inching back towards normality, despite remaining risks from COVID-19.
U.S. health officials said on February 16 they are preparing for the next phase of the COVID-19 pandemic as Omicron-related cases decline, including updating CDC guidance on mask-wearing and shoring up U.S. testing capacity.
Delivery of Pfizer Inc. and BioNTech SE’s vaccine to combat the Omicron COVID-19 variant was delayed by several weeks due to a slower-than expected data gathering process, BionTech Chief Executive Ugur Sahin told Germany’s Bild.
